Bienvenue dans notre banque interrogeable de ressources et de documentation sur l’approvisionnement plus sécuritaire et autres sujets connexes.
Responding to letters about this article: https://www.cmaj.ca/content/195/27/E934
Ressources
Letter | 2023
Clinical guidance, Harm reduction, About prescribers, Safer supply, Stimulants
Our objective was to provide preventive care recommendations that promote health equity by prioritizing effective interventions for people experiencing disadvantages.
Guidelines | 2023
Equity, Clinical guidance
Are higher doses of buprenorphine treatment for opioid use disorder associated with improved retention in treatment when use of fentanyl (vs heroin) is more prevalent?
Original research | 2023
Substitution/OAT, Transitions in care/treatment, Clinical guidance
Inpatient guidelines for methadone titration do not exist, whereas outpatient guidelines lack flexibility and do not consider individual opioid tolerance.
Original research | 2023
Hospitals, Substitution/OAT, Transitions in care/treatment, Clinical guidance, About prescribers, Outcomes
Commentary | 2023
Safer supply, Stimulants, About prescribers, Policy/Regulatory, Clinical guidance
Case study | 2022
Withdrawal, Clinical guidance, Hospitals
Case study | 2023
Withdrawal, Hallucinogens/psychedelics, Clinical guidance
This clinical considerations document is based on a narrative literature review and expert consensus and will specifically address considerations for changes to the clinical practice of
Lit review | 2023
Substitution/OAT, Withdrawal, Clinical guidance, About prescribers
The present meta-analysis was conducted to evaluate the efficacy and safety of tramadol in the treatment of opioid withdrawal.
Original research | 2023
Withdrawal, Clinical guidance
Measure general substance use severity, to examine for differential item functioning (DIF) across substances (i.e., sedatives, opioids, amphetamines, cocaine, and cannabis).
Original research | 2023
Clinical guidance
Case study | 2023
Wrap-around services, Illegal drugs, Clinical guidance
Opioid analgesics are commonly used for acute low back pain and neck pain, but supporting efficacy data are scarce.
Original research | 2023
Chronic pain, Clinical guidance
Report | 2023
Overdose, Clinical guidance, Workplace
Guidelines | 2023
Clinical guidance, Substitution/OAT
Guide | 2023
les guides de pratique clinique, à propos des prescripteurs, à propos des pharmaciens, la surdose, la mortalité, la politique / le cadre de réglementation
Guidelines | 2022
Overdose, Clinical guidance
This study analysed the perspectives from a broad range of service providers, whose work was impacted or related to the RMG, to elucidate a nuanced narrative regarding the perceived facilitators an
Thesis | 2023
About prescribers, Safer supply, Barriers and enablers, Clinical guidance
We conducted a policy scan of UDS guidelines, examining the published clinical practice guidelines for each Canadian province and extracting all relevant data in March 2017.
Guidelines | 2018
Clinical guidance, Substitution/OAT, About prescribers
We aimed to examine comprehensively the evidence for agreement between self-reported and biologically measured illicit drug use across all major illicit drug classes, biological indicators, populat
Lit review | 2023
About PWUD, Illegal drugs, Clinical guidance
